{
  "abstract": "Background Crosstalk between inflammation and the immune system plays an important role in tumor malignant progression, immune evasion, and immunotherapy efficacy. This study aims to explore the significance of inflammation-associated gene ribosomal-binding protein 1 (RRBP1) in modulating tumor malignant progression and immune escape.Methods This study was used transcriptome, proteomic and in vivo anti-programmed death-ligand 1 (PD-L1) antibody CRISPR Cas9 screening data to identify RRBP1 as an inflammation-immune-associated gene in bladder cancer (BC). Immunohistochemistry, single-cell RNA sequencing, multiplex immunofluorescence, flow cytometry, RNA sequencing, and animal experiments were used to study the role of RRBP1 in regulating tumor malignant progression and immunotherapy efficacy.Results RRBP1 overexpression promoted the proliferation and metastasis of BC both in vitro and in vivo. RNA sequencing and single-cell RNA sequencing revealed that RRBP1 inhibition activated immune-associated pathways and reshaped the tumor immune microenvironment by altering the infiltration of CD8 + T-cell subpopulations, thereby enhancing antitumor immunity. Mechanistically, RRBP1 inhibition enhances the secretion of CXCL10 by cancer cells, which binds to CXCR3 on CD8+ T cells to promote interferon-γ and Granzyme B expression. Furthermore, genetic and pharmacological inhibition of RRBP1 sensitizes tumors to anti-PD-L1 therapy.Conclusions Our findings highlight RRBP1 as an inflammation-immune-associated gene that inhibits tumor progression and improves immunotherapy efficacy by regulating the CXCL10-CXCR3 axis in the tumor microenvironment.",
  "authors": [
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Chengquan Shen"
    },
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Changxue Liu"
    },
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Ding Hu"
    },
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Huaixi Ge"
    },
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Cheng Li"
    },
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Ruize Qin"
    },
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Xinzhao Zhao"
    },
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Yonghua Wang"
    },
    {
      "affiliations": [
        "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China"
      ],
      "name": "Haitao Niu"
    }
  ],
  "title": "Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer",
  "uid": "f0305243-a9d9-5bc0-b358-e8d7a67c24de"
}